22 February 2021
Visiongain has published a new report on Organ Preservation Solutions Market Report 2021-2031: Forecasts By Solution Type (Viaspan, Custodiol HTK, Renograf, Hypothermosol, Perfadex, Lifor, HBS Solution, siRNA Transplant Solutions, and Others), By Preservation Technique (Hypothermic Perfusion Preservation, Static Cold Storage, and Others), By Organ Type (Kidneys, Liver, Lungs, Heart, and Other Organs), By End User (Hospitals, Organ Transplant Centers, Specialty Clinics, and Others), By Distribution Channel (Direct Tender, and Retail Sales) PLUS Profiles of Leading Manufacturing Companies and Regional and Leading National Market Analysis. PLUS COVID-19 Recovery Scenarios.
Global Organ Preservation Solutions market was valued at US$ xx Million in 2020 and is projected to reach at a market value of US$ xx Million by 2031. North America dominated the global Organ Preservation Solutions market and is projected to witness CAGR of XX% during the first half of the forecast period i.e. 2021 to 2031.
COVID-19 Impact on Organ Preservation Solutions Market
COVID-19 impact through different recovery models such as V-shaped, U-shaped, W-shaped, and L-shaped; has been taken into consideration while estimating and forecasting the Organ Preservation Solutions market. Different recovery scenarios are also included in the report for all the segments and regions/nation. The recovery scenarios based on which market has been forecasted and analysed herein the report are mentioned below:
Growing Organ Transplantation and Organ Donation around the World
The number of organ transplantation and organ donation is increasing very significantly and it is expected to continuously rise over the forecast period. Increasing organ transplantation and organ donation is creating a huge demand for the organ preservation solutions for preservation of organs in the organ in the organ banks. Due to which growing organ transplantation and organ donation around the world is working as a driver for the Organ Preservation Solutions market.
Increasing Geriatric Population around the World
An increase in geriatric population is being referred for and an increase in accessibility for organ transplant, and there is very rapid growth in organ donations from older adults or geriatric populations.
The rapid increase in organ transplant and organ donations is being registered because of the rapid increase in Geriatric population around the world from the last few decades. All regions are facing a huge increase in the number of geriatric populations. For instance: According to the United Nations, Department of Economic and Social Affairs, the Population Division geriatric population (persons aged 65 or over) was 702.9 million in 2019. Rapid increase in organ transplant and organs donations caused by the increasing geriatric population is also increasing the demand for organ preservation solutions around the world. Due to the increasing geriatric population around the world is working as a driver for the organ preservation solutions market.
Increasing focus on Healthcare Infrastructure
Governments from all over the world are shifting their focus on infrastructure and advanced healthcare facilities and also taking necessary steps to create or modify healthcare infrastructure. Healthcare infrastructure in developing nations are undergoing tumultuous changes from the last few years and each change is only for a better healthcare delivery, and to incorporate all the sections of the population. Increasing focus on healthcare infrastructure is expected to increase public spending which is expected to create new opportunities for the organ preservation solutions market, Moreover, the public private spending will also aid the market growth during the forecast period. Due to this reason the factor is creating various opportunities for the organ preservation solutions market.
Top companies (Dr. Franz Köhler Chemie GmbH, Bristol-Myers Squibb Company, Teva Pharmaceutical Industries Ltd, and XVIVO Perfusion AB) constitute more than XX% share of the global Organ Preservation Solutions market. Other companies profiled in the report include: BioLife Solutions, Inc., 21st Century Medicine, Bridge to Life Ltd, Accord Healthcare, OrganOx Limited, Accord Healthcare others Some of the key developments are listed below:
● In 2018, XVIVO Perfusion received U.S. FDA approval Perfadex Plus, which is a 'ready-to-use' product for cold preservation of lungs. The approval had helped the company widened revenue generation from a market focused product portfolio.
● In 2017, Accord Healthcare had acquired Essential Pharmaceuticals, which is a leading organ preservation solution provider. The acquisition had helped the company to increase its market share in the organ preservation solutions market.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.
21 July 2021
Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.
20 July 2021
Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.
14 July 2021
Digital innovation in clinical trials and renewed focus on home production will ensure a high growth market for supply chain optimisation.